Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

NDC-0524

Source date not recordedAnalyse record ↗

Preclinical aggregate-selective antibody targeting nitrated alpha-synuclein in Parkinson's disease and related synucleinopathies.

Modality
monoclonal antibody selective for pathologically nitrated alpha-synuclein
Availability (US)
Preclinical; IND-enabling work complete, first-in-human Phase 1/2a evaluation planned
Biomarkers
nitrated alpha-synuclein; alpha-synuclein aggregate spread; cerebrospinal-fluid nitrated synuclein
Hallmark targeted
loss of proteostasis, intracellular protein aggregation, chronic inflammation
Kind
investigational biologic